BNP Paribas Call 80 NOVN 20.06.20.../ DE000PC1JHA2 /
11/10/2024 15:47:00 | Chg.+0.11 | Bid17:14:32 | Ask17:14:32 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.17EUR | +5.34% | 2.18 Bid Size: 49,000 |
2.20 Ask Size: 49,000 |
NOVARTIS N | 80.00 CHF | 20/06/2025 | Call |
GlobeNewswire
30/07
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08/07
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
GlobeNewswire
26/06
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire
13/06
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire
16/04
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire
11/04
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Develo...
GlobeNewswire
14/03
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
GlobeNewswire
28/02
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
28/02
PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invas...
GlobeNewswire
10/01
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire
05/01
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire
02/01
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...